Review of current authorship guidelines and the controversy regarding publication of clinical trial data

Biotechnology Annual Review

Volumn 9, Issue , 2003, Pages 303-313

  Foote, MaryAnn ^a  

^a AMGEN INC   (United States)

Author keywords

Biotechnology medical biotechnology; Clinical research publication of trials; Good publication practices; Uniform requirements for biomedical journals; Vancouver conventions

Indexed keywords

BIOTECHNOLOGY; CLINICAL RESEARCH; DRUG INDUSTRY; DRUG INFORMATION; MEDICAL LITERATURE; METHODOLOGY; POLICY; RESEARCH ETHICS; REVIEW; WRITING; BIOMEDICAL AND BEHAVIORAL RESEARCH; CLINICAL TRIAL; DOCUMENTATION; ETHICS; INTERPERSONAL COMMUNICATION; LEGAL ASPECT; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; PUBLICATION; PUBLISHING; SCIENTIFIC MISCONDUCT; STANDARD; UNITED STATES;

BIOMEDICAL AND BEHAVIORAL RESEARCH;

AUTHORSHIP; CLINICAL TRIALS; COMMUNICATION; DOCUMENTATION; GUIDELINES; OWNERSHIP; PERIODICALS; PUBLISHING; SCIENTIFIC MISCONDUCT; UNITED STATES;

EID: 1542755296     PISSN: 13872656     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1387-2656(03)09009-4     Document Type: Review

References (15)

1. Tufts Center for the Study of Drug Development, http://www.tufts.edu/med/ csdd/Nov30CostStudyPressRelease.html (accessed 6 June 2002).
2. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. N Engl J Med 1997;336:309-315.
3. Kaushansky K. Removing the cloud from industry-sponsored, multicentered clinical trials. Blood 2001;98:2001 (editorial).
4. Smith R. Maintaining the integrity of the scientific record. Br Med J 2001;323:588 (editorial).
5. Dong BJ, Young R and Rapaport B. The nonequivalence of thyroid products. Drug Intell Clin Pharmacol 1986;20:77-78.
6. Eckert CH. Bioequivalence of levothyroxine preparations: industry sponsorship and academic freedom. JAMA 1997;277:1200-1201 (editorial).
7. Rennie D. Thyroid storm. JAMA 1997;277:1238-1243 (editorial).
8. Spigelman MK. Bioequivalence of levothyroxine preparations for treatment of hypothyroidism. JAMA 1997;277:1199-1200 (letter).
9. Dong BJ, Hauck WW, Gambertoglio JG, et al. Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. JAMA 1997;277:1205-1213.
10. Bezwoda WR, Seymour L and Dansey RD. High dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomised trial. Eur J Cancer 1995a;31A:S76.
11. Bezwoda WR, Seymour L and Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995b;13:2483-289.
12. Antman KH. High-dose chemotherapy in breast cancer: the end of the beginning? Biol Blood Marrow Transplant 2000;6:49-475.
13. Weiss RB, Rifkin RM, Stewart FM, et al. High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study. Lancet 2000;18:355:999-1003.
14. Weiss RB, Gill CG and Hudis CA. An on-site audit of the South African trial of high-dose chemotherapy for metastatic breast cancer and associated publications. J Clin Oncol 2001;19:2771-2777.
15. International Conference on Harmonisation, Guidance for Industry, E6 Good Clinical Practice: Consolidated Guidance, April 1996, http://www.ifpma.org/ pdfifpma/e6.pdf, accessed 4 March 2002.